



Harnessing oncolytic virus-mediated immunity /

Fournier, Philippe,
editor

Schirmacher, V,
editor

Frontiers Media SA,
2015

Monografía

Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic addresses various strategies how to optimize OVs anti-tumor activity

<https://rebiunoda.pro.baratznet.cloud:38443/OpacDiscovery/public/catalog/detail/b2FpOmNlbGVicmF0aW9uOmVzLmJhcmF0ei5yZW4vMjYxOTAxMDA>

Título: Harnessing oncolytic virus-mediated immunity topic editors: Philippe Fournier and Volker Schirmacher

Editorial: Switzerland Frontiers Media SA 2015

Descripción física: 1 online resource (110 pages) illustrations; digital, PDF file(s)

Mención de serie: Frontiers Research Topics

Nota general: Bibliographic Level Mode of Issuance: Monograph

Bibliografía: Includes bibliographical references

Restricciones de acceso: Open Access. Unrestricted online access star

Detalles del sistema: Mode of access: internet via World Wide Web

Lengua: English

ISBN: 9782889193080 ebook)

Autores: Fournier, Philippe, editor Schirmacher, V, editor

Baratz Innovación Documental

- Gran Vía, 59 28013 Madrid
- (+34) 91 456 03 60
- informa@baratz.es